Items which should not routinely be prescribed in primary care - doxazosin modified release by all Sub-ICB Locations
Why it matters:
Doxazosin is an alpha-adrenoceptor blocking drug that can be used to treat hypertension and benign prostatic hyperplasia. There are two oral forms of the medication (immediate release and prolonged release) and both are taken once daily.
Prolonged-release doxazosin has historically cost much more than the immediate-release formulation. However as of January 2026 the 4mg immediate-release formulation is significantly more expensive than the prolonged-release formulation. As the NHS England guidance is still in place, we continue to show this measure, but we have removed from the overall low-priority measure, and are regularly reviewing the appropriateness.
Description: Cost of doxazosin modified release per 1000 patients
Explore:
Tagged as: Cardiovascular system, Cost Saving, NHS England - items which should not routinely be prescribed in primary care (or browse all measures)
Sub-ICB Locations are ordered by mean percentile over the past six months. Each chart shows the results for the individual Sub-ICB Location, plus deciles across all Sub-ICB Locations in the NHS in England.
View measure for NHS England combined →
Fetching data...